Results 71 to 80 of about 801 (115)

Polypharmacy With Second-Generation Antipsychotics: A Review of Evidence

Journal of Psychiatric Practice, 2008
The objective of this study was to review the prevalence of polypharmacy with second-generation antipsychotics (SGAs) in clinical practice, pharmacological reasons for such practice, and the evidence for and against such polypharmacy.Clinical trial reports, case reports, and reviews were identified by a PubMed literature search from 1966 through ...
Anand K, Pandurangi, Alican, Dalkilic
openaire   +2 more sources

Hyperglycaemia in patients treated with second generation antipsychotics.

La Clinica terapeutica, 2013
The association of second generation antipsychotic medications and hyperglycaemia has been reported for Caucasian populations but is unknown for asian patients who unfortunately are predisposed to diabetes. We report the findings from a health quality improvement project which tracked patients with schizophrenia and schizoaffective disorder newly ...
Mahendran, R., Hendricks, M.M.
openaire   +2 more sources

Rehospitalization Risk with Second-Generation and Depot Antipsychotics

Annals of Clinical Psychiatry, 2003
Decreasing hospital admissions is important for improving outcomes for people with schizophrenia. Second-generation antipsychotics (SGAs) are better tolerated for long-term therapy than traditional medications and may contribute to a lower rehospitalization risk, but have not been compared to depot forms with regard to long-term outcomes.
Robert R, Conley, Deanna L, Kelly, Raymond C, Love, Robert P, McMahon   +3 more
openaire   +2 more sources

Second-generation antipsychotics for obsessive compulsive disorder

Cochrane Database of Systematic Reviews, 2010
Obsessive compulsive disorder (OCD) is a psychiatric disorder which has been shown to affect 2 to 3.5% of people during their lifetimes. Inadequate response occurs in 40% to 60% of people that are prescribed first line pharmaceutical treatments (selective serotonin reuptake inhibitors (SSRIs)).
Katja, Komossa, Anna M, Depping, Magdalena, Meyer, Werner, Kissling, Stefan, Leucht   +4 more
openaire   +2 more sources

Second-generation antipsychotics and bone turnover in schizophrenia

Schizophrenia Research, 2014
Accumulating evidence suggests that patients with schizophrenia are exposed to a high risk of osteoporosis/osteopenia caused by long-term antipsychotic treatment. The degree of bone mineral density (BMD) loss that a given antipsychotic may cause is not known.
Kyoji, Okita, Nobuhisa, Kanahara, Motoi, Nishimura, Toshihiko, Yoshida, Norio, Yasui-Furukori, Tomihisa, Niitsu, Taisuke, Yoshida, Masatomo, Ishikawa, Hiroshi, Kimura, Fumio, Nomura, Masaomi, Iyo   +10 more
openaire   +2 more sources

Antipsychotic and antidepressive effects of second generation antipsychotics

European Archives of Psychiatry and Clinical Neuroscience, 2005
Second generation antipsychotics display antidepressive effects in schizophrenic patients that are more pronounced than those of traditional neuroleptics and that go beyond antidepressive effects secondary to the reduction of positive symptoms.
openaire   +2 more sources

Age-Dependent Metabolic Effects of Second-Generation Antipsychotics in Second-Generation Antipsychotic-Naïve French Canadian Patients

Journal of Child and Adolescent Psychopharmacology, 2010
Patients receiving second-generation antipsychotics (SGAs) may experience secondary metabolic effects such as weight gain, as well as changes in lipid and glucose metabolism. These effects are well documented in adults; however, fewer studies are available concerning their occurrence and their evolution in children and adolescents.The aim of this study
Geneviève, Roy, Alain, Bedard, Paul-André, Desmarais, France, Jourdain, Sylvie, Allen, Danielle, Michaud, Leila, Ben Amor   +6 more
openaire   +2 more sources

Second-Generation Antipsychotics and Risk of Cerebrovascular Accidents in the Elderly

Journal of Clinical Psychopharmacology, 2005
Concern has been recently raised for risperidone and olanzapine, possibly associated with cerebrovascular events in placebo-controlled trials conducted in elderly subjects with dementia. We investigated the relationship between exposure to second-generation antipsychotics (SGAs) and occurrence of cerebrovascular accidents in the elderly.
Percudani M., Barbui C., Fortino I., Tansella M., Petrovich L.   +4 more
openaire   +2 more sources

Second-Generation Antipsychotics

Drug Safety, 2006
Six second-generation antipsychotics (SGAs), aripiprazole, clozapine, olanzapine, quetiapine, risperidone and ziprasidone, are currently US FDA approved. The aim of this review is to investigate whether sex differences exist for efficacy and adverse effects of these drugs.Sex-related differences have been shown in the pharmacokinetics of cytochrome ...
Wolfgang, Aichhorn, Alexandra B, Whitworth, Elisabeth M, Weiss, Josef, Marksteiner   +3 more
openaire   +2 more sources

Augmentation With Second-Generation Antipsychotics

2018
Second-generation antipsychotic augmentation: Effective strategy High burden of side effects Quetiapine Target symptoms: anxiety and sleeping difficulties Side effects: sedation and weight gain Aripiprazole Target symptoms: anhedonia, reduced motivation Side effects: movement disorders and anxiety When to augment versus switch?
openaire   +1 more source